|
시장보고서
상품코드
2084798
근육 경직 시장 : 약제 종류별, 투여 경로별, 유통 채널별, 지역별Muscle Spasticity Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
근육 경직 시장은 2026년에 114억 달러 규모에 달할 것으로 추정되며, 2033년까지 237억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.9%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 114억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 8.90% | 예측 금액(2033년) | 237억 달러 |
근육이 뻣뻣해지거나 수축하는 상태를 근육 경직이라고 합니다. 근육 경직은 척수 손상, 뇌 손상, 근위축성 측삭 경화증(ALS) 및 다발성 경화증(MS) 등의 질환을 비롯한 다양한 상태에서 나타납니다. 이는 근육의 움직임을 제어하는 신경 자극이 손상되거나 차단되었을 때 발생합니다. 근육 경직은 대화나 동작, 스트레칭에 어려움을 초래할 수 있습니다.
근육 경직의 증상으로는 근육 긴장 증가, 불수의적 운동, 비정상적인 자세, 통증이나 불편감, 뼈나 관절의 변형, 기능 저하 외에도 다양한 것들이 있습니다. 경직은 통증을 유발하거나, 일상생활이나 수면에 지장을 주거나, 기능 저하로 이어지는 경우 치료를 받아야 합니다. 치료법은 환자의 필요, 희망, 목표에 따라 결정됩니다. 치료에는 물리치료, 작업치료, 깁스 고정 및 보조기 착용, 경구약 투여 등이 포함됩니다. 경우에 따라서는 수술이 필요할 수도 있습니다. 경구용 약물은 증상이 일상생활이나 수면에 지장을 주는 경우에만 사용됩니다. 일반적인 약물로는 바클로펜, 단트로렌 나트륨, 보툴리눔톡신, 디아제팜 등이 있습니다.
시장 역학
근육 경직 치료제의 신약 출시와 규제 당국의 승인이 증가함에 따라, 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2021년 7월, 멜츠 그룹 산하에서 신경독소 분야의 선두주자인 멜츠 테라퓨틱스(Merz Therapeutics)와, 테이진 그룹의 헬스케어 사업 핵심 기업인 테이진 파마 주식회사는, 테이진 파마가 일본 후생노동성으로부터 하지 경련 치료를 목적으로 하는 50, 100, 또는 200 단위의 근육 내 주사용 신경독소 치료제 ‘제오민(인코보툴리눔톡신 A)’의 판매에 대한 추가 승인을 획득했다고 공동으로 발표했습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
- 세계 근육 경직 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 소개하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 근육 경직 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 근육 경직 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 근육 경직 시장 : 약제 종류별(2021-2033년)
제5장 세계의 근육 경직 시장 : 투여 경로별(2021-2033년)
제6장 세계의 근육 경직 시장 : 유통 채널별(2021-2033년)
제7장 세계의 근육 경직 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
KSM 26.07.20Muscle Spasticity Market is estimated to be valued at USD 11.4 Bn in 2026 and is expected to reach USD 23.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 11.4 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.90% | 2033 Value Projection: | USD 23.7 Bn |
When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.
Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient's needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan's Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global muscle spasticity market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Baclofen
- Botulinum Toxin
- Diazepam
- Tizanidine
- Dantrolene Sodium
- Others
- By Route of Administration (Revenue, USD Bn, 2021-2033)
- Oral
- Intramuscular
- Others
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Ipsen Pharma
- Allergan
- Acorda Therapeutics, Inc.
- Merz Pharma
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Beximco Pharmaceuticals Ltd.
- Johnson & Johnson Private Limited
- Zydus Cadila
- Hoffmann-La Roche Ltd.
- Elite Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Highlights
- Pipeline Analysis
- Regulatory Scenario
- Product Launches / Approvals
- PEST Analysis
- PORTER's Analysis
- Merger, Collaboration and Acquisitions Scenario
4. Global Muscle Spasticity Market, By Drug Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Baclofen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Botulinum Toxin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diazepam
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tizanidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dantrolene Sodium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Muscle Spasticity Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Muscle Spasticity Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Muscle Spasticity Market, By Region, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2021-2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Acorda Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merz Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Beximco Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Private Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Elite Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- Ipsen Pharma
9. Section
- Research Methodology
- About us
